Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271 - Wikidata - thesis-toulmin - TriplyDB

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271

http://www.wikidata.org/entity/Q27650074

about

Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth FAK and paxillin, two potential targets in pancreatic cancer Nuclear FAK: a new mode of gene regulation from cellular adhesions FAK in cancer: mechanistic findings and clinical applications Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes Crystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG Conformation Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer Integrin-matrix clusters form podosome-like adhesions in the absence of traction forces Myosin II activity regulates vinculin recruitment to focal adhesions through FAK-mediated paxillin phosphorylation.Activation of focal adhesion kinase through an interaction with β4 integrin contributes to tumorigenicity of colon cancer Evolving Therapies and FAK Inhibitors for the Treatment of Cancer Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway.Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.Myosin IIA/IIB restrict adhesive and protrusive signaling to generate front-back polarity in migrating cells Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model Focal adhesion kinase and endothelial cell apoptosis.Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation.Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer.Molecular and cellular impact of Psoriasin (S100A7) on the healing of human wounds.Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.Role of kinase-independent and -dependent functions of FAK in endothelial cell survival and barrier function during embryonic development.Adrenergic signaling regulates mitochondrial Ca2+ uptake through Pyk2-dependent tyrosine phosphorylation of the mitochondrial Ca2+ uniporter Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.Targeting Pyk2 for therapeutic intervention Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis Pyk2 promotes tumor progression in multiple myeloma Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.Role for NUP62 depletion and PYK2 redistribution in dendritic retraction resulting from chronic stress Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.

P2860

Q24613142-F7A628D9-5807-4C9B-ACBF-25AAF2108A4B Q26765360-3A07C5C8-4B00-43C6-8D36-FCADC29E0A35 Q26864184-EC7F9422-D4B3-45F5-AE93-88BCE234FA47 Q27026533-40728330-F639-423E-9928-6838A4B1EDB4 Q27314883-1B3776C8-F2E1-4C9F-860B-C23E24E1B61F Q27652985-F303939D-61F3-4E28-820E-5396806B36B6 Q28550689-855F6BF8-3DB9-48E3-80B6-77B7349D82F4 Q28568664-79FB112D-3A6B-44C9-974D-58E2B324FAF4 Q28586815-4EEFF155-D120-4097-AF01-D98D01FC6382 Q28771754-0E90FDAE-30DD-4761-BB0E-DEC204E93220 Q28972291-56AE827F-BD44-4707-B74F-953E0562CC4C Q30278951-6A9D2907-85BD-456B-B104-FC3988BE2D61 Q30422676-DE64D50B-D013-44FD-A90A-F040601D6028 Q30424344-5ABF3C15-53F0-4201-8213-98793832653E Q30430251-0F69F659-4817-4E67-84BB-DE0EB436ECA5 Q30435351-04B06548-6C80-48FC-8A88-92A6E53F745D Q30459602-EF6F03BF-528B-40A8-B5DF-23EBE274B897 Q30486408-91AA2DB7-857D-4A4E-A223-4F23A2F314D6 Q30495320-27900C80-39CC-4451-9C1D-F33441F5D40C Q30502431-A2931BA6-8892-4F86-88CA-790FC9407E4C Q33724031-BA0775E9-BEA1-4C52-A6B7-4B158694FB30 Q33737191-0E1F29AD-A1D3-47F1-A9E8-6F7C67F9B932 Q33775577-FE1E6249-5463-465C-8576-747255E277C7 Q33787214-B5F92023-0819-4C0E-8D1E-D7348D268E74 Q33794045-9FC0B09C-1901-498D-AC5B-A73653762956 Q33911213-87AA19E7-7871-4EAC-810D-6D490092A3DF Q33916059-C7A8C5A8-7887-4F34-935B-2C81E1B822BD Q33974822-ECA31228-A138-460B-8DA4-C754C557797F Q33998634-F2AF7EEF-D645-4C6D-A5FB-370BFFD5518C Q34021043-E0AAE48C-DEDE-43CC-8064-4CE164EAABA6 Q34103876-779A7FAA-6261-4796-977E-685A470ECB58 Q34103928-816CB375-DC56-41F2-9811-DA75599E3C79 Q34109901-AF6A6E27-7E59-4F0B-AB58-2D9AB28CBFF4 Q34146883-A71CA0C1-C1A0-4B92-8235-9E604A614618 Q34193347-83FA9ADC-013D-4E87-AD46-A25F5508C341 Q34374676-CAD6AAC0-7D25-4C63-912A-843148A79787 Q34398382-189DFDF9-A43D-40D3-BFD0-FDB17BDB6A07 Q34495723-E163FCF6-6B51-42DF-B51F-D3FAFEE1E8A0 Q34525933-F3D2CEBF-D3A0-4CFD-B546-F4EDE2D74C3B Q34754045-E07D0ADC-91EB-4976-A6A7-BE08AB4C1EA3

P2860

Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271

http://www.wikidata.org/entity/Q27650074

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@ast

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@en

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@nl

type

label

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@ast

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@en

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@nl

prefLabel

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@ast

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@en

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@nl

P1433

Q27650074-E592CC1E-3595-4F92-B308-490271D1F08A

P1476

Q27650074-169CDB28-453E-4286-AAF9-9D8A6454BB3B

P2093

Q27650074-00154AC1-1EE6-4179-A32E-80DEF044594A

Q27650074-06ABB098-9D32-4B82-BC5D-0C598F75785C

Q27650074-0E010075-CE9E-4081-AB27-04076784E4BB

Q27650074-19165AFA-6927-462A-A385-787CFD4C43DC

Q27650074-1DBA8ED5-4303-48B3-BB69-096FB158F158

Q27650074-2B43EF91-AF64-48CC-B137-1A6B395A1D14

Q27650074-37184819-ED2F-4CBD-BA89-FB33903CA729

Q27650074-4D3E2CC3-F301-41A5-8A1B-DD3A4F1BB82E

Q27650074-57CDC5DB-9A4A-416B-9CDA-3F1409959183

Q27650074-5C47BA7D-05BF-45CF-9EDB-D28D5938CB18

P304

Q27650074-DA196CF8-838C-457D-9B1E-5D10E0B02A79

P31

Q27650074-16E506DC-60BC-4930-8D64-54CEA42AC870

P3181

Q27650074-62D8DFE1-50E1-4C36-81A0-872995585DB3

P356

Q27650074-20795F4F-AB65-4FCE-9EC8-F3D66C70671D

P407

Q27650074-D58E608F-07AB-41BE-8DE2-C7A1386E1F96

P433

Q27650074-598FD3D6-BDC0-44D4-A442-577263D65112

P478

Q27650074-019E000F-A080-4967-A1C8-5F20D81B6636

P577

Q27650074-220BE409-AF4D-4E5D-892C-2ADFD889D3EB

P5875

Q27650074-73DBCE17-07DE-4BD3-B637-A37239B8ABBF

P698

Q27650074-B50A58EE-7082-432B-BE83-1E5E8A616BEF

P921

Q27650074-AEB1AC2B-69BD-4DA6-96A0-1AAC1B8C2FCA

P3181

P356

0008-5472.CAN-07-5155

P1433

Cancer Research

P1476

Antitumor activity and pharmac ...... n kinase inhibitor, PF-562,271

@en

P2093

Beth Cooper

http://www.w3.org/2001/XMLSchema#string

Catherine Hulford

http://www.w3.org/2001/XMLSchema#string

Christofer Autry

http://www.w3.org/2001/XMLSchema#string

Daniel Richter

http://www.w3.org/2001/XMLSchema#string

Earling Emerson

http://www.w3.org/2001/XMLSchema#string

Eric Marr

http://www.w3.org/2001/XMLSchema#string

Erika Schmitt

http://www.w3.org/2001/XMLSchema#string

Ethan Ung

http://www.w3.org/2001/XMLSchema#string

Felix Vajdos

http://www.w3.org/2001/XMLSchema#string

Jing Lin

http://www.w3.org/2001/XMLSchema#string

P304

1935-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4894491

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-07-5155

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5512220

http://www.w3.org/2001/XMLSchema#string

P698

18339875

http://www.w3.org/2001/XMLSchema#string

P921